Summary
This prediction ended on 11.09.14 with a price of €3.16. The SELL prediction by Mori8 for Evotec SE closed nearly unchanged from the start price. Mori8 has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | -0.928% | -0.928% | -41.074% | -71.549% |
| iShares Core DAX® | 3.178% | 0.980% | 15.331% | 18.044% |
| iShares Nasdaq 100 | 2.972% | 0.925% | 39.831% | 50.841% |
| iShares Nikkei 225® | 0.545% | -4.556% | 17.661% | 3.434% |
| iShares S&P 500 | 2.367% | 0.833% | 30.000% | 44.095% |
According to Mori8 what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Fair valuation
High Investments for future growth
Very good company culture
Innovative
Growths faster than the competition
Sustainability is important
Medium risks for its business
Top 10 in its market
Small cyclical dependencies
Very Future proof/growth oriented business model
Cons
Comments by Mori8 for this prediction
In the thread Evotec AG diskutieren
DE0005664809
Achten !!
(Vom Mitglied beendet)